Computational tools have the potential to enable rapid material-free developability assessments of large molecule candidates. With wide spanning roles across early discovery through to downstream development activities, when utilized effectively, computational techniques can shorten timelines and enhance the cost-effectiveness of biologic drug development.
However, as indicated by how the space lacks comparatively behind the small molecule and medicinal chemistry fields, this wave of disruption is not without challenges. Scientific, behavioural and operational mindset shifts are still required to ensure successful implementation and large-scale adoption of these technologies within the discovery and development workflow.
The CDD for Biologics Summit remains solely dedicated to exploring the power of in silico tools to de-risk biologics drug development. Our mission has been, and remains, to provide a forum that unite stakeholders from across pharma, academia and software providers along with the end users in computational biology, structural biology and bioinformatics to define current capabilities, and realise how these tools can be further adapted to add immediate value to biologics pipelines.
Focused principally on design and developability of antibodies, this year’s case studies will reveal the applications of these methods to other biotherapeutic modalities, from early drug discovery through to late preclinical development.
Discussion will centre around means to overcome data availability, model validation and standardization issues.
Join us to identify market trends, enhance cost-effectiveness, shorten biologics development timelines and accelerate program development with insights from our industry leading speaker faculty.